Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, and its clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells. Since risk-adapted therapy is becoming standard of care, there is an urgent need for a precise risk stratification model to assist in therapeutic decision-making. While progress has been made, there remains a significant opportunity to improve patient stratification to optimize treatment and to develop new therapies for high-risk patients. The MM DREAM Challenge aims to accelerate the development and evaluation of such risk models in multiple myeloma.
Multiple Myeloma DREAM Challenge
The Multiple Myeloma DREAM Challenge aims to accelerate the development and evaluation of models for risk stratification of patients to improve therapeutic decision-making.
Other Assessments & Benchmarking research studies
The ICGC-TCGA DREAM Somatic Mutation Calling - RNA Challenge is an international effort to improve standard methods for identifying cancer-associated rearrangements in RNA sequencing (RNA-seq) data.Learn More